The US Food and Drug Administration has cleared a test that can help detect ovarian cancer in a pelvic mass in women who are already scheduled for gynecological surgery.
The blood test, called OVA1, is not a screening test or a test meant to diagnose ovarian cancer. Rather, it helps determine what type of surgery should be done and by whom. It is not meant to replace other diagnostic and clinical procedures.
By testing for levels of five proteins that change due to ovarian cancer, OVA1 identifies some women who will benefit from referral to a gynecological oncologist for their surgery, despite negative results from other clinical and radiographic tests for ovarian cancer.
If other test results suggest cancer, referral to an oncologist is appropriate even with a negative OVA1 test result.